NCT01215084View on ClinicalTrials.gov

A Pharmacokinetics (PK) and Safety Study of Oral Fampridine-PR 10 mg in Chinese, Japanese, and Caucasian Adult Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

October 31, 2010

Primary Completion Date

November 30, 2010

Study Completion Date

November 30, 2010

Conditions
Healthy
Interventions
DRUG

BIIB041 (Fampridine-PR)

A single 10mg dose tablet by mouth of fampridine prolonged-release (PR) for all participants

Trial Locations (2)

Unknown

Research Site, Melbourne

Research Site, Shatin

Sponsors

Lead Sponsor

Biogen

Collaborators (1)

Acorda Therapeutics
All Listed Sponsors
collaborator

Acorda Therapeutics

INDUSTRY

lead

Biogen

INDUSTRY